Goldman Sachs’s Marker Therapeutics MRKR Stock Holding History

Goldman Sachs’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,382	Closed	-$32K	–	6783
2021 Q4	$32K	Sell	3,382 -1,024	-23%	-$13.6K	﹤0.01%	6321
2021 Q3	$74K	Sell	4,406 -9,218	-68%	-$189K	﹤0.01%	5968
2021 Q2	$380K	Buy	13,624 +11,114	+443%	+$293K	﹤0.01%	5373
2021 Q1	$56K	Sell	2,510 -249	-9%	-$5.7K	﹤0.01%	5932
2020 Q4	$40K	Sell	2,759 -1,538	-36%	-$23.9K	﹤0.01%	5401
2020 Q3	$64K	Sell	4,297 -1,405	-25%	-$25.6K	﹤0.01%	5153
2020 Q2	$118K	Buy	+5,702	New	+$125K	﹤0.01%	4953
2020 Q1	–	Sell	-4,325	Closed	-$124K	–	5435
2019 Q4	$124K	Buy	4,325 +2,872	+198%	+$104K	﹤0.01%	5018
2019 Q3	$74K	Buy	+1,453	New	+$85.9K	﹤0.01%	4996
2019 Q2	–	Sell	-7,175	Closed	-$474K	–	5274
2019 Q1	$474K	Buy	+7,175	New	+$419K	﹤0.01%	4441
2017 Q2	–	Sell	-1,059	Closed	-$48K	–	6883
2017 Q1	$48K	Buy	+1,059	New	+$47.1K	﹤0.01%	6297

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return

Goldman Sachs's MRKR Position: Q1 2022 in Review

Goldman Sachs sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 3,382 shares — an estimated $32K sold.

Goldman Sachs first reported a position in MRKR in Q1 2017 and held it in 11 quarters. The position peaked at $474K in Q1 2019. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

Goldman Sachs reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
Goldman Sachs sold 3,382 Marker Therapeutics shares in Q1 2022, an estimated $32K.
Goldman Sachs first reported a position in Marker Therapeutics in Q1 2017 and held it in 11 quarters.
Goldman Sachs's Marker Therapeutics position peaked at $474K in Q1 2019.
49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.